Treatment Information

Back

Breast Cancer treatment details. Chemotherapy, Biologic therapy.

Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Chicago, IL
Treatments:Chemotherapy, Biologic therapyHospital:Northwestern University Feinberg School of Medicine
Drugs:Journal:Link
Date:Jan 2013

Description:

Patients:
This phase 2 study involved female HER2-negative advanced breast cancer patients who were divided into two separate treatment groups. Group A had 119 patients with an average age of 50.6 years. Group B had 118 patients with a median age of 53.1 years.

Treatment:
Patients in group A were treated with the chemotherapy agent paclitaxel and the biologic therapy agent sorafenib, which is a multikinase inhibitor that interferes with cancer cell growth.

Patients in group B were treated with paclitaxel and a placebo.

Toxicities:
Adverse event-related deaths were reported in group A; causes included malaria, liver dysfunction, and heart attack. Grade 4 neutropenia, mucosal inflammation, and shortness of breath were also reported.

There were three adverse event-related deaths in group B due to meningitis and an unknown cause. Grade 4 neutropenia and grade 3 nerve toxicities were also reported.

Results:
The median overall survival for group A and B was 16.8 and 17.4 months, respectively.

Support:
This study was partially supported by Onyx Pharmaceuticals and Bayer Healthcare Pharmaceuticals.

Correspondence: Dr. William J. Gradishar; email: [email protected]



Back